CA2252505C - Nouvelles cellules presentant l'antigene, procede de preparation associe, et leur utilisation comme vaccins cellulaires
- Google Patents
Nouvelles cellules presentant l'antigene, procede de preparation associe, et leur utilisation comme vaccins cellulaires
Download PDF
Info
Publication number
CA2252505C
CA2252505CCA002252505ACA2252505ACA2252505CCA 2252505 CCA2252505 CCA 2252505CCA 002252505 ACA002252505 ACA 002252505ACA 2252505 ACA2252505 ACA 2252505ACA 2252505 CCA2252505 CCA 2252505C
Authority
CA
Canada
Prior art keywords
apcs
cells
antigen
lymphocytes
histamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IDM Immuno Designed Molecules
Original Assignee
IDM Immuno Designed Molecules
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP96401099Aexternal-prioritypatent/EP0808897A1/fr
Application filed by IDM Immuno Designed MoleculesfiledCriticalIDM Immuno Designed Molecules
Publication of CA2252505A1publicationCriticalpatent/CA2252505A1/fr
Application grantedgrantedCritical
Publication of CA2252505CpublicationCriticalpatent/CA2252505C/fr
Micro-Organisms Or Cultivation Processes Thereof
(AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Abstract
L'invention concerne des cellules présentant l'antigène dérivées des monocytes (MD-APC), caractérisées par les propriétés suivantes: elles présentent à leur surface les antigènes CD14 et CD64 avec une intensité moyenne comprise entre 5 et 200 environ, les antigènes CD80 et CD86 avec une intensité moyenne comprise entre 20 et 200 environ, l'antigène CD40 et le récepteur du mannose avec une intensité moyenne comprise entre 50 et 500; elles sont sensiblement dépourvues des antigènes de surface CD1a et CD1c; elles présentent une propriété de phagocytose; elles présentent la propriété de stimuler la prolifération de lymphocytes allogènes.
CA002252505A1996-05-211997-05-15Nouvelles cellules presentant l'antigene, procede de preparation associe, et leur utilisation comme vaccins cellulaires
Expired - Fee RelatedCA2252505C
(fr)
Efficient presentation of tumor idiotype to autologous T cells by CD83+ dendritic cells derived from highly purified circulating CD14+ monocytes in multiple myeloma patients
GMCSF in the absence of other cytokines sustains human dendritic cell precursors with T cell regulatory activity and capacity to differentiate into functional dendritic cells
Interferon γ impairs the ability of monocyte-derived dendritic cells to present tumour-specific and allo-specific antigens and reduces their expression of CD1a, CD80 and CD4
Treatment of autoimmunity and transplant rejection through establishment and/or promotion of tolerogenic processes by fibroblast-mediated reprogramming of antigen presenting cells